Protagenic Therapeutics Inc Stock News

FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW YORK, NY / ACCESS Newswire / August 20, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based treatments for stress-related neu...

As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor antagonist did not show activity in the same model. NEW YORK, NY / ACCESS Newswire / June 30, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company focused on novel n...

NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuropsychiatric disorders, today announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by reg...

NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-related neuropsychiatric disorders, today announced the appointment of Bill Nichols Jr. as President. This strategic leadership addition, combined with a thoughtful optimization of the Company's manag...